Wisconsin Assembly Bill AB950

Wisconsin 2023-2024 Regular Session

• Introduced: 1/12/24
• Refer: 1/12/24
• Report Pass: 2/12/24
• Refer: 2/12/24
• Failed: 4/15/24

Caption

Excepting xylazine testing materials from the definition of drug paraphernalia and civil and criminal liability exemptions for distributing and administering xylazine testing products.

Impact

The enactment of AB950 would have substantial implications for the state laws governing drug testing and public health. By including xylazine in the exemption list, the bill acknowledges the need to adapt legislation to respond to the evolving landscape of substance use and potential overdoses. This legislative move is expected to promote the responsible distribution and utilization of xylazine testing products, ultimately aiming to mitigate harm associated with drug use by allowing easier accessibility to testing tools.

Summary

Assembly Bill 950 (AB950) introduces legislative changes focusing on xylazine testing products. The bill aims to exempt materials used for testing xylazine from the definition of drug paraphernalia, which is significant in light of current laws that categorize all testing materials as such. This exemption is crucial for enhancing public safety regarding substance testing and aligns with existing exceptions for testing fentanyl. The bill aims to protect individuals distributing and administering these testing materials from both civil and criminal liability, provided they follow the manufacturer's instructions.

Contention

Notably, there may be concerns from parties focused on drug regulation and public health. While the bill could significantly help in identifying xylazine in substances, critics might argue about the potential for misuse or insufficient oversight in the distribution due to the liability exemptions provided. Discussions around the responsibility of manufacturers and distributors may arise, pushing for stricter guidelines to ensure safe testing practices and minimize the risk of harm from inaccurate results or improper administration of xylazine testing products.